

MENDELIAN INHERITANCE


Helen M Kingston




Gregor Mendel 1822-84

Disorders caused by a defect in a single gene follow the patterns of inheritance described by Mendel. Individual disorders of this type are often rare but are important because they are numerous (3000-4000 single gene traits have been listed¹). Risks within an affected family are usually high and are calculated by knowing the mode of inheritance and details of the family pedigree.

Autosomal dominant disorders




Autosomal dominant disorders affect both males and females and can often be traced through many generations of a family. Affected people are heterozygous for the abnormal allele and transmit the gene for the disease to half their offspring, whether male or female. The disorder is not transmitted by family members who are unaffected themselves. Estimation of risk is therefore apparently simple, but in practice several factors may cause difficulties in counselling families.



Firstly, the age of onset of a disorder may be variable and people with a defective gene, who are destined to become affected, may remain without signs or symptoms well into adult life. Young people at risk may not know whether they have inherited the disorder and will transmit it to their children, at a time when they are planning their own families. Detection of people carrying the mutant gene before symptoms become apparent may therefore be important in conditions such as Huntington's chorea and myotonic dystrophy.

The severity of many dominant conditions also varies considerably among affected members within a family. The likely severity in any affected offspring is difficult to predict, and a mildly affected parent may have a severely affected child, as illustrated by tuberous sclerosis, in which a parent with only skin manifestations of the disorder may have an affected child with infantile spasms and severe mental retardation.

New mutation may account for the presence of a dominant disorder in a subject who does not have a family history of the disease. When a disorder arises by new mutation the risk of recurrence in future pregnancies for the mother of the affected child is negligible. Care must be




Tuberous sclerosis. Top left: severely affected boy with fits and mental retardation; top right: adenoma sebaceum; bottom left: ash leaf depigmentation; bottom right: periungual fibroma

Examples of autosomal dominant disorders

Achondroplasia	Huntington's chorea
Acute intermittent porphyria	Myotonic dystrophy
Adult polycystic kidney disease	Noonan's syndrome
Alzheimer's disease (some cases)	Neurofibromatosis
Epidermolysis bullosa (some forms)	Osteogenesis imperfecta (some forms)
Facioscapulohumeral dystrophy	Polyposis coli
Familial hypercholesterolaemia	Tuberous sclerosis


taken to exclude a mild form of the condition in one or other parent before giving this reassurance. New mutation accounts for most cases of achondroplasia, a condition that can be easily excluded in the parents. On the other hand, neurofibromatosis may arise by new mutation or be present in mild form in one parent. In dominant conditions an apparently normal parent may occasionally carry a germline mutation; this is associated with a considerable risk of recurrence. A dominant disorder in a person with a negative family history may alternatively indicate non-paternity.




Lack of penetrance in A

A few dominant disorders show lack of penetrance—that is, a person who inherits the gene does not develop the disorder. In this case people who are not affected cannot be completely reassured that they will not transmit the disorder to their children. The risk is, however, fairly low, not exceeding 10%, because when penetrance is high an unaffected person is unlikely to be a gene carrier, and when it is low the chance of a gene carrier developing the disorder is correspondingly small.

Non-genetic factors may also influence the expression of dominant genes—for example, diet in hypercholesterolaemia and drugs in porphyria.





Homozygosity for a dominant disorder



Homozygosity for dominant genes is uncommon, unless two people with the same disorder marry. This may happen preferentially with certain conditions, such as achondroplasia. Homozygous achondroplasia is a lethal condition and the risks for offspring of such parents are therefore: 25% homozygous affected (lethal); 50% heterozygous affected; 25% homozygous normal. Thus two out of three living children will be affected.

Autosomal recessive disorders




Autosomal recessive disorders occur in a person whose healthy parents both carry the same recessive gene. The risk of recurrence for future offspring of such parents is 25%. Unlike autosomal dominant disorders there is generally no family history. Although the defective gene may be passed from generation to generation, the disorder generally only appears within a single sibship—that is, within one group of brothers and sisters.

In white Europeans the commonest autosomal recessive disorder is cystic fibrosis, and about one in 20 people in the population is a carrier.

Consanguinity increases the risk of a recessive disorder because both parents are more likely to carry the same defective gene, which has been inherited from a common ancestor. The rarer the condition the more likely it is that the parents were related before marriage. Overall, the increased risk to parents who are first cousins of having a child with severe abnormalities is fairly low (3% above the risk in the general population), and this includes the risk of autosomal recessive disorders.

The offspring of an affected person will be healthy heterozygotes and can be affected only if the other parent is also a gene carrier. This is unlikely except in a consanguineous marriage.



Consanguinity and autosomal recessive inheritance




Hurler's syndrome: coarsening of facial features

Examples of autosomal recessive disorders

Congenital adrenal hyperplasia	Homocystinuria
Cystic fibrosis	Hurler's syndrome (mucopolysaccharidosis I)
Deafness (some forms)	Laurence-Moon-Biedl syndrome
Diastrophic dwarfism	Occulocutaneous albinism
Epidermolysis bullosa (some forms)	Phenylketonuria
Friedreich's ataxia	Sickle cell disease
Galactosaemia	Tay-Sachs disease
Haemochromatosis	Thalassaemia

Autosomal recessive disorders are commonly severe, and many of the recognised inborn errors of metabolism follow this type of inheritance. Many complex malformation syndromes are also due to autosomal recessive genes, and their recognition is important in the first affected child in a family because of the 25% risk of recurrence. Prenatal diagnosis for recessive disorders may be possible by performing biochemical assays or looking for structural abnormalities in the fetus.

X linked recessive disorders



Angiokeratoma in Fabry's disease

In X linked recessive conditions only males are affected and the disorder is transmitted through healthy female carriers. Occasionally a heterozygous female may show some features of the condition.

A female carrier will transmit the disorder to half her sons, and half her daughters will be carriers. All the daughters of an affected male are obligate carriers whereas none of the sons are affected. X linked recessive disorders cannot be transmitted by a healthy male. Many X linked recessive disorders are severe or lethal during early life, so that the affected males do not reproduce.

Examples of X linked disorders

Recessive

Anhidrotic ectodermal dysplasia	Haemophilia A, B
Becker's muscular dystrophy	Hunter's syndrome (mucopolysaccharidosis II)
Colour blindness	Lesch-Nyhan syndrome
Duchenne muscular dystrophy	Menkes's syndrome
Fabry's disease	Mental retardation with or without fragile site
Glucose-6-phosphate dehydrogenase deficiency	Occular albinism


Dominant

Incontinentia pigmenti	Rickets resistant to vitamin D
Orofacioidigital syndrome	

An X linked recessive condition should be considered when the family history indicates affected males in different generations of the family. Family history is, however, not always positive as new mutations are fairly common.


Identifying female gene carriers in the family requires interpretation of the family pedigree and the results of specific tests to identify the carriers.

X linked dominant disorders




An X linked dominant gene will give rise to a disorder in both hemizygous males and heterozygous females. The gene is transmitted in families in the same way as X linked recessive genes, giving rise to an excess of affected females. In some disorders the condition is lethal in hemizygous males. In this case there will be fewer males than expected in the family, all of whom will be healthy, and an excess of females, half of whom will be affected.

Y linked disorders



In Y linked disorders only males are affected, with transmission being directly from father to son with the Y chromosome. This pattern of inheritance has been suggested for such conditions as porcupine skin, hairy ears, and webbed toes. In most conditions in which Y linked inheritance has been postulated the actual mode of inheritance is probably autosomal dominant, with other factors causing sex limitation.

Cytoplasmic inheritance



Diagrammatic representation of human egg

Unlike sperm, the egg contains cytoplasm as well as a nucleus. Certain inherited characteristics are probably influenced or wholly determined by cytoplasmic elements. These may be biochemical factors, mitochondrial DNA, or mitochondria themselves and would always be maternally derived. Although not proved, cytoplasmic inheritance may account for the maternal transmission of the congenital form of myotonic dystrophy, the preponderance of paternal transmission in Huntington's chorea of juvenile onset, the transient myasthenia seen in the offspring of mothers with myasthenia gravis, and the absence of father to son transmission of Leber's optic atrophy. In addition, at least one type of myopathy due to mitochondrial dysfunction is maternally transmitted.

1 McKusick VA. *Mendelian inheritance in man. Catalogs of autosomal dominant, autosomal recessive and X-linked phenotypes.* 8th ed. Baltimore: John Hopkins, 1988.

The illustrations of tuberous sclerosis were reproduced by kind permission of Professor P S Harper, Institute of Medical Genetics for Wales, Cardiff.

Dr Helen M Kingston, MD, is consultant clinical geneticist at St Mary's Hospital, Manchester.

ANY QUESTIONS

In general practice antibiotics are usually prescribed in sufficient quantity for five days' treatment and dispensed with an injunction to take the whole course. Is there a sound scientific basis to this advice?

The "appropriate" length of antimicrobial treatment may vary depending on diagnosis, complicating factors, the age of the patient, and the clinical setting. For some infections lengthy treatment is appropriate, so that osteomyelitis or endocarditis may require many weeks' chemotherapy. In uncomplicated urinary tract infection a single dose may suffice.^{1,2} It is desirable to minimise the length of treatment so far as is consistent with attaining the objective. Objectives may vary: remission of symptoms, defervescence, and return of some laboratory or radiological feature to normal are examples.

In hospital it may be easy to arrange for chemotherapy to be stopped in a day or two if clinical objectives have been achieved. Since this may not be readily arranged in general practice a pragmatic choice of the length of treatment based on clinical experience is often made, five to seven days often being selected for urinary or respiratory infections. While this is often effective, it also commonly represents overtreatment, which is regrettable because it inconveniences the patient or the relatives, may give rise to adverse events, adds to selective pressures for antibiotic resistance in bacteria, and increases costs.

The common injunction to finish the course, often not complied with by patients because they feel better and forget, is probably intended to minimise the emergence of resistance. This supposed motivation is ill founded because the index pathogen is unlikely to become resistant at the site of infection because of underdosing. The emergence of resistant strains of bacteria usually occurs in the commensal flora, and its extent is related to the amount of drug ingested. Short courses are to be preferred. If the injunction to complete the course is not given for that reason it is

merely an exercise in unscientific authoritarianism.—R N GRÜNEBERG, consultant microbiologist, London

- 1 Harbord RB, Grüneberg RN. Treatment of urinary tract infection with a single dose of amoxicillin, co-trimoxazole, or trimethoprim. *Br Med J* 1981;283:1301-2.
- 2 Bailey RR. *Single dose therapy of urinary tract infection.* Sydney: ADIS Health Science Press, 1983:125.

If a patient taking β blockers develops anaphylactoid shock would adrenaline be recommended despite their interaction or, if not, is there an alternative?

The beneficial effects of adrenaline in anaphylaxis depend on both α and β receptors. Stimulation of α receptors induces an increase in blood pressure in the shocked patient by promoting arteriolar constriction. It probably also reduces capillary permeability. Cells that release humoral factors important in the genesis of anaphylaxis are stabilised by a β_2 adrenergic action, and bronchodilatation relies on the same mechanism. These β mediated effects must be attenuated when treatment is given to a patient taking β blockers, especially if the agent is not a so called selective one. I do not know, however, of any clinical evidence that β blockade increases the dangers of anaphylaxis or reduces the efficacy of treatment. Adrenaline remains the treatment of choice, but a β_2 agonist such as salbutamol could be given as an additional agent in severe cases. In appropriate doses this should help to overcome any β_2 blockade that may be hindering recovery.—D A CHAMBERLAIN, consultant cardiologist, Brighton

Skidmore IF. Beta-agonists as mast cell stabilizers. In: Kay AB, ed. *Asthma: clinical pharmacology and therapeutic progress.* Oxford: Blackwell, 1986.